Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
The 10-K against last year's

236 changes: 74 added, 52 removed, 107 reworded, 3 quiet changes

10-K Feb 26, 2026 vs Feb 25, 2025

10-K 0001628280-26-012240 (Feb 26, 2026) vs 10-K 0001628280-25-007715 (Feb 25, 2025) Not compared: Legal Proceedings.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

320 paragraphs · 30 new · 103 reworded · 16 gone · 10-K Feb 26, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 124 · 47% changed Every version of it
In addition, our contract manufacturers may not be able to manufacture the materials required for our products or product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug substances, products, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of products and product candidate material for further preclinical testing and clinical trials. Our third-party manufacturers also may not meet our manufacturing requirements. Furthermore, changes in the manufacturing process or procedures, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA’s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards, for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties, any of which could be costly to us and could result in a delay or shortage of product.
Paragraph 247 · 47% changed Every version of it
In addition to such fines, failure to comply with the requirements of the GDPR or similar national legislation may result in temporary or definitive bans on data processing and other corrective actions and subject us to litigation and/or adverse publicity, which could have material adverse effects on our reputation and business. As a result of the implementation of the GDPR, and other laws and regulations, we are required to put in place additional mechanisms to ensure compliance with the data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the European Union, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audits. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider, we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.
Paragraph 66 · 38% changed Every version of it
The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired, as described in “Business—Government Regulation—FDA Regulation—Abbreviated New Drug Applications for Generic Drugs” in Part I, Item 1 of this report, but such exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for such drugs. Competition that our products or product candidates may face from generic drugs could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our products or, if and when approved, product candidates, are not afforded the appropriate periods of non-patent exclusivity.
Paragraph 68 · 37% changed Every version of it
The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired, as described in “Business—Government Regulation—FDA Regulation—Abbreviated New Drug Applications for Generic Drugs” in Part I, Item 1 of this report, but such exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for such drugs. Competition that our drug products or product candidates may face from generic drugs could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our products or, if and when approved, product candidates, are not afforded the appropriate periods of non-patent exclusivity.
Paragraph 218 · 37% changed Every version of it
Pharmakon Loan Agreement” in the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this report). Under the Pharmakon Loan Agreement, we will be required to pay to Pharmakon, for the account of the lenders, a prepayment premium or a make-whole premium, as applicable, plus certain fees or expenses set forth in the Pharmakon Loan Agreement in the event that we prepay, or are required to prepay, voluntarily or pursuant to a mandatory prepayment obligation under the Pharmakon Loan Agreement (e.g., upon certain asset sales, a change of control of the Company and specified other events, subject to certain exceptions), all or part of the then-outstanding term loans under the Pharmakon Blackstone Loan Agreement, in each case, subject to certain exceptions as set forth in the Pharmakon Blackstone Loan Agreement.
Paragraph 78 · 36% changed Every version of it
If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.
Paragraph 283 · 33% changed Every version of it
We may in the future seek to acquire or invest in businesses, products or technologies that we believe could complement or expand our portfolio or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing businesses or products. In addition, we may not be able to find and identify desirable acquisition targets or be successful in entering into an agreement with any particular target or consummating any such agreement. Even if we do consummate an acquisition, in connection therewith we may be required to issue equity (thereby diluting our current stockholders) or debt, we may not be able to integrate successfully the acquired personnel, operations and technologies, or effectively manage the combined business following the acquisition, or the acquired business could otherwise fail to meet our expectations, which, in each case, could have a material adverse effect on our business projections, financial condition, results of operations and prospects.
Paragraph 36 · 32% changed Every version of it
•clinical protocols or study procedures may not be adequately designed or followed by the investigators; investigators, including ensuring that all data is accurately recorded and reported;

MD&A

116 paragraphs · 44 new · 51 reworded · 36 gone · 10-K Feb 26, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 68 · 50% changed
For the year ended December 31, 2024, interest income was $14.7 million compared to $15.8 million for the year ended December 31, 2023. Net foreign currency losses were $0.6 million for the year ended December 31, 2024 compared to $1.0 million for the year ended December 31, 2023. For the year ended December 31, 2023, 2025, we recognized a one-time loss on extinguishment of debt associated with the repayment of $17.3 million as a result of the term loans under payoff of the Athyrium Credit Agreement was $29.0 million. Pharmakon Term Loan.
Paragraph 39 · 49% changed
Years The following table summarizes our research and development expenses, including program specific costs and shared or indirect operating costs recognized as research and development expenses for the periods indicated (in thousands):Years Ended December 31, 2025 2024 2023 Research and development expenses by program: Berotralstat $ 45,033 11,171 $ 42,835 10,301 BCX17725 17,304 12,388 Avoralstat 9,497 7,547 Factor D Program 24,072 94,517 BCX17725 32,417 19,133 456 8,534 Research, discovery and preclinical programs 17,677 12,733 Compensation and related personnel costs 51,015 57,094 Stock-based compensation 29,510 31,285 Other research, preclinical non-program specific and development indirect costs 73,116 60,081 27,957 32,033 European ORLADEYO business (excluding stock-based compensation) 1,539 2,723 Total research and development expenses $ 166,126 $ 174,638 $ 216,566
Paragraph 53 · 49% changed
Cost of product sales Sales and marketing expenses (excluding stock-based compensation) increased to $146.6 million for the years year ended December 31, 2024 and 2023 was $12.3 2025 from $116.9 million and $4.5 million, respectively. for the year ended December 31, 2024. The increase in cost of product sales was primarily due to increases in ORLADEYO and RAPIVAB direct sales and an increase in driven by the inventory reserve in the current year period. following:
Paragraph 95 · 48% changed
•our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies if and governmental agencies or other third parties; when needed;
Paragraph 44 · 46% changed
Research and development expenses decreased to $174.6 •$1.8 million for the year ended December 31, 2024 from $216.6 million for the year ended December 31, 2023, primarily due to decreased expenses driven by the discontinuation and close-out of the Factor D programs, BCX10013 and BCX9930. Investment in BCX17725 and other research, preclinical and development costs, comprised of avoralstat and other early-phase pipeline programs, increased primarily due to investigational new drug application-enabling activities and the initiation of the Phase 1 trial evaluating BCX17725. Further, there was an increase decrease in stock-based compensation expense as a result primarily due to the acceleration of stock-based compensation expense upon adoption of the Retirement Policy (as defined in “Note 12—Stock-Based Compensation—Retirement Policy” 13—Stock-Based Compensation” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report) adopted in July 2024, 2024 and a decrease in research and development expenses resulting from a decrease related headcount, partially offset by an increase in general restricted stock unit awards granted; and administrative expense allocations.
Paragraph 31 · 45% changed
For the year ended December 31, 2024, total revenues were $450.7 million compared to $331.4 million for the year ended December 31, 2023. The increase in total revenues was due to a $111.7 •$168.7 million increase in ORLADEYO net revenue, including royalties, excluding revenues associated with our European ORLADEYO business, primarily due to an increase in volume of direct sales of ORLADEYO due to both an increase in volume, ORLADEYO, which was driven by strong patient demand, an increase in price, and an increase in price. The increase in total revenues was also due to an increase in other revenues the rate of $7.6 million, primarily due to an increase in direct sales of RAPIVAB. paid shipments; and
Paragraph 67 · 44% changed
Interest expense for interest rate during the year ended December 31, 2024 period in which the debt was $98.5 million compared to $108.2 million for the year ended December 31, 2023. The outstanding in 2025. In addition, there was a decrease in interest expense was primarily due to a decrease in the effective interest rate related to the 2021 RPI associated with our OMERS Royalty Purchase Agreement (as defined in “Note 8—Royalty 9—Royalty Financing Obligations—ORLADEYO and Factor D Inhibitors” Obligations” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report) and as result of a decrease in interest expense associated with the borrowings under the Athyrium Credit Agreement (as defined below), which was repaid on April 17, 2023, partially offset by an increase in interest expense associated with the interest accrued on the Tranche A Loan of $300.0 million under the Pharmakon Loan Agreement (as defined below), which was funded on April 17, 2023. lower outstanding principal balance.
Paragraph 3 · 43% changed
We are a global biotechnology company with a focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with hereditary angioedema (“HAE”) these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and other rare diseases. We leverage our expertise in structure-guided drug design with developed internally for the goal prevention of developing HAE attacks. Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule small molecule and injectable protein therapeutics to target difficult-to-treat targeting a range of rare diseases. In addition to these These programs are being pursued through both internal discovery efforts and development efforts, strategic business development. By utilizing our business strategy includes the successful commercialization of these drugs, as well as self-funding all of these efforts by achieving existing commercial capabilities and increasing profitability. By focusing primarily on rare disease markets, we believe that we can more effectively control the optimize our costs of, and our strategic allocation of financial strategically allocate resources toward, post-approval commercialization. to support long-term, sustainable growth.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors204 words changed in this paragraph; it is 30% similar to last year's version.
Pharmakon On January 23, 2026, we entered into a Loan Agreement” Agreement (the “Blackstone Loan Agreement”) with Blackstone Alternative Credit Advisors LP and Blackstone Life Science Advisors L.L.C., (together, “Blackstone”), as the Blackstone representatives thereunder, the guarantors from time to time party thereto, the lenders from time to time party thereto, and Wilmington Trust, National Association, as agent, pursuant to which the lenders funded initial term loans in the Notes aggregate principal amount of $400.0 million. Subject to the Consolidated Financial Statements included in Part II, Item 8 of this report). mutual agreement between the Company, Blackstone and the lenders, we may request additional term loans up to an aggregate amount not exceeding $150.0 million. Under the Pharmakon Blackstone Loan Agreement, we will be required to pay to Pharmakon, for the account of the lenders, lenders a prepayment premium or a make-whole premium, as applicable, plus certain fees or expenses set forth in the Pharmakon Loan Agreement applicable in the event that that, prior to the fourth anniversary of the closing date of the Blackstone Loan Agreement, we prepay, prepay or repay, or are required to prepay, prepay or repay, voluntarily or pursuant to a mandatory prepayment obligation under the Pharmakon Blackstone Loan Agreement (e.g., upon a change of control of the Company and specified other events, subject to certain exceptions), all or part of the then-outstanding term loans under the Pharmakon Loan Agreement, in each case, subject to certain exceptions set forth in the Pharmakon Loan Agreement.

Source: Item 1A, 10-K 0001628280-26-012240 vs Item 1A, 10-K 0001628280-25-007715

Accounting Policies164 words changed in this paragraph; it is 41% similar to last year's version.
BioCryst Pharmaceuticals, Inc. (the “Company”) is a global biotechnology company with a focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by the Company’s deep commitment to improving the lives of people living with hereditary angioedema (“HAE”) and other rare diseases. these conditions. The Company leverages its expertise in structure-guided drug design with has built a robust commercial infrastructure to support the goal successful commercialization of developing ORLADEYO®, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company’s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to target difficult-to-treat targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule and protein therapeutics through the process known as structure-guided drug design.

Source: Item 8, Note 1 – Significant Accounting Policies and Concentrations of Risk, 10-K 0001628280-26-012240 vs Item 8, Note 1 – Significant Accounting Policies and Concentrations of Risk, 10-K 0001628280-25-007715

MD&A158 words changed in this paragraph; it is 60% similar to last year's version.
The Pharmakon Blackstone Loan Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limit the our ability of the Company and certain of its our subsidiaries to, among other things, dispose of assets; assets, engage in mergers, acquisitions, acquisitions and similar transactions; transactions, incur additional indebtedness; indebtedness, grant liens; liens, make investments; investments, pay dividends or make distributions or certain other restricted payments in respect of equity; equity, prepay certain other indebtedness; indebtedness, enter into restrictive agreements; agreements, undertake fundamental changes; changes or amend certain material contracts, among other customary covenants, in each case subject to certain exceptions. These A failure to comply with the covenants in the Blackstone Loan Agreement, or an occurrence of any other event of default, could cause us permit the lenders under the Blackstone Loan Agreement to declare the borrowings thereunder, together with accrued interest and fees, and any applicable yield protection premium, to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders’ permission or without repaying all obligations outstanding under the Pharmakon Loan Agreement. A breach of any of these covenants could result in an event of default under the Pharmakon Loan Agreement. As of December 31, 2024, we were in compliance with the negative covenants under the Pharmakon Loan Agreement. immediately due and payable. See “Note 9—Debt—Pharmakon Loan Agreement” 21—Subsequent Events” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about our obligations under the Pharmakon Blackstone Loan Agreement.

Source: Item 7, 10-K 0001628280-26-012240 vs Item 7, 10-K 0001628280-25-007715

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of BCRX's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
The market price of our common stock may decline as a result of the Merger if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial analysts or the effect of the Merger on our financial results is not consistent with the expectations of financial analysts. Accordingly, holders of our common stock following the consummation of the Merger may experience a loss as a result of a decline in the market price of such common stock. In addition, a decline in the market price of our common stock following the consummation of the Merger could adversely affect our ability to issue additional securities if needed and to obtain additional financing in the future.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Combining Astria with our business may be more difficult, costly or time consuming than expected and the combined company may fail to realize the anticipated benefits and synergies of the Merger.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
The success of the Merger will depend, in part, on the ability to realize the anticipated benefits and cost savings from combining our business and Astria’s business. To realize the anticipated benefits and synergies from the Merger, we must successfully integrate and combine our businesses in a manner that permits those benefits and synergies to be realized. If we are not able to successfully achieve these objectives, the anticipated benefits of the Merger may not be realized fully or
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
at all or may take longer to realize than expected. In addition, the actual cost savings and anticipated benefits of the Merger could be less than anticipated, and integration may result in additional unforeseen expenses.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
An inability to realize the full extent of the anticipated benefits of the Merger, as well as any delays encountered in the integration process, could have an adverse effect on the revenues, levels of expenses and operating results of the combined company, which may adversely affect the value of our common stock.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Prior to completion of the Merger, we and Astria have operated independently. It is possible that the integration process could result in the loss of key employees, the disruption of our business or inconsistencies in standards, controls, procedures and policies that adversely affect our ability to maintain relationships with employees and counterparties or to achieve the anticipated benefits and cost savings of the Merger. Integration efforts may also divert management attention during this transition period, which may have an adverse effect on our Company.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
We are in the early stages of integrating Astria into our business, and unknown or unanticipated risks associated with Astria’s business or product candidates could adversely affect us.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 67
AddedRisk Factors
Although we conducted due diligence on Astria prior to consummation of the Merger, we are still relatively new to Astria’s business and its operations, including its product candidates. As a result, we may not yet be aware of all material risks, liabilities, or challenges associated with Astria’s business or product candidates (in particular, navenibart), including risks that were not identified or fully appreciated during our due diligence process. There can be no assurance that our due diligence identified all risks, liabilities, or other material matters, that all material issues that could be uncovered through a customary level of due diligence were identified, or that factors outside of our control will not later arise. Even where due diligence successfully identifies certain risks, unexpected risks may arise, and previously known risks may materialize in a manner that is inconsistent with our preliminary risk assessments or assumptions.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
We expect that we will incur substantial expenses in connection with completion of the Merger and combining the business, operations, networks, systems, technologies, policies and procedures of the two companies. Although we have assumed that a certain level of transaction and combination expenses will be incurred, there are a number of factors beyond our control that could affect the total amount or the timing of our combination expenses. There can be no assurance that the anticipated benefits related to the integration of Astria with our business will be realized to offset these transaction and integration expenses over time.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In connection with the payment of the merger consideration, we issued 17.5% of the shares of our common stock issued and outstanding immediately prior to the effective time of the Merger. The issuance of these new shares of our common stock may result in fluctuations in the market price of our common stock, including a stock price decrease. In addition, former Astria stockholders or holders of other Astria securities may decide not to hold the shares of our common stock that they have received in connection with the Merger, and our stockholders may decide to reduce their investment in us as a result of the changes to our investment profile as a result of the Merger, which may result in further fluctuations in the market price of our common stock, including a stock price decrease.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
We have sustained operating losses for the majority of our corporate history and expect to continue to incur operating losses and negative cash flows unless and until revenues reach a level sufficient to support ongoing operations.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
to complete the development and commercialization of our products and product candidates or continue operations” in this section for further discussion of the capital requirements for our development and commercialization efforts.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The policies of the FDA and other regulatory authorities may change, including as a result of changes in presidential administration of the United States, and additional government regulations or executive orders may be enacted that could
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
In September 2024, we entered into a contract with ASPR for the procurement of up to 95,625 doses over a five-year period of RAPIVAB for the treatment of influenza. The contract is structured with a 12-month base ordering period and four optional 12-month ordering periods, which the U.S. Government can exercise on an annual basis. While ASPR executed the first ordering period, there is no guarantee that the U.S. Government will exercise any additional ordering periods. In addition, changes in U.S. Government budgets and agendas may result in the reduction, delay or elimination of funding or in a decreased emphasis on the procurement of RAPIVAB. Even if any optional ordering period is exercised, there can be no assurance that we or our manufacturers will be able to fully meet the demand for RAPIVAB with respect to this or any future arrangement.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts, and which may create a disadvantage and additional risks to us as compared to competitors that do not have U.S. Government contracts. As a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
to private sector commercial companies, and we could suffer serious harm to our reputation if allegations of impropriety were made against us. We could be subject to severe penalties, including legal actions and liabilities, in the event that we are unable to comply with delivery requirements or any other provision of a U.S. Government contract.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
On April 17, 2023, we entered into the $450.0 million Pharmakon Loan Agreement (the “Pharmakon Loan Agreement”) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders, and closed on an initial term loan thereunder in the principal amount of $300.0 million. As of December 31, 2024, we had an outstanding principal balance under the Pharmakon Loan Agreement of $323.7 million, inclusive of the Pharmakon PIK Interest Payments (as defined in “Note 9—Debt—
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The United Kingdom’s decision to withdraw from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The United Kingdom’s exit from the European Union, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the European Union, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. The long-term effects of Brexit will depend in part on how the current and
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
Our ability to raise additional capital if and when needed may liquidity needs will largely be limited and may greatly depend upon our sustained success in commercializing and achieving market acceptance of ORLADEYO and determined by the success of operations in regard to the commercialization of our current drug development programs, products, particularly ORLADEYO, the progression of our product candidates, including the progress, timeline and ultimate outcome of the our development programs (including, but not limited to, formulation progress, long-term human safety studies, clinical trial investigations, and carcinogenicity, drug-drug interaction, toxicity, or other required studies) described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview—Products and Product Candidates” in Part II, Item 7 of this report, studies), as well as any post-approval studies for our products. products, and our ability to execute our budget plans.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Under the Pharmakon Loan Agreement, we will be required to pay to Pharmakon, for the account of the lenders, a prepayment premium or a make-whole premium, as applicable, plus certain fees or expenses set forth in the Pharmakon Loan Agreement in the event that we prepay, or are required to prepay, voluntarily or pursuant to a mandatory prepayment obligation under the Pharmakon Loan Agreement (e.g., upon certain asset sales, a change of control of the Company and specified other events, subject to certain exceptions), all or part of the then-outstanding term loans under the Pharmakon Blackstone Loan Agreement, in each case, subject to certain exceptions as set forth in the Pharmakon Blackstone Loan Agreement.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
An event of default will also occur if, among other things, we fail to pay amounts due under the Pharmakon Blackstone Loan Agreement, we fail to repay certain other indebtedness having an aggregate principal amount in excess of a threshold amount, an insolvency event occurs with respect to us, judgments for the payment of money in excess of a threshold amount are entered into against us, a material adverse change in our business, assets, properties, liabilities, or condition occurs, or a material impairment of our ability to perform our obligations under the Pharmakon Blackstone Loan Agreement occurs, occurs or certain negative regulatory events occur, including, without limitation, certain withdrawal events with respect to ORLADEYO, or we fail to make required payments under our Royalty Purchase Agreements. occur.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Currently, we have established collaborative relationships, including with, among others, third-party distributors for ORLADEYO in certain markets, with Torii for ORLADEYO in Japan, with Neopharmed for the commercialization of ORLADEYO in Japan, with third-party distributors for ORLADEYO in certain other markets, and Europe, with each of Shionogi and Green Cross for the development and commercialization of peramivir. peramivir, and with Clearside for the development of avoralstat with Clearside’s SCS Microinjector®.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If we are unable to raise capital if and when needed, we may need to adjust our operations” in this section and See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” in Part II, Item 7 of this report for additional information about our liquidity risks needs, capital requirements, potential funding alternatives, and capital requirements. adequacy of available funds.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We have experienced, and may continue to experience, experienced significant growth in the number of our employees and the scope of our operations in the United States and internationally, particularly in the areas of drug development, regulatory affairs, sales, marketing, and distribution. operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Identifying, selecting, and in-licensing or acquiring products or product candidates requires substantial expense and technical and financial expertise, and if we are unable to effectively manage our pipeline or integrate viable products or product candidates into our business on acceptable terms, or at all, our business and drug development efforts could suffer.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We also Although most of our revenues and expenses are denominated in U.S. dollars, we have foreign currency exposure to fluctuations in other foreign currencies, such as the Swiss Franc, Danish Krone, Swedish Krona, Norwegian Krone, Euro, British Pound, Japanese Yen and Canadian Dollar.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We are also performing research on or developing products for the treatment of several other rare or difficult-to-treat diseases, including Netherton syndrome, DME, and diseases of the complement system. we expect to encounter significant competition for our pharmaceutical products and product candidates.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In addition, future revenue from sales of ORLADEYO is subject to uncertainties and will depend on several factors, including including, but not limited to, the success of our and our partners’ commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government payors, the number of patients receiving free product, the conversion of patients from our clinical trials and early access programs to commercial customers, our pricing strategy, and market trends.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If we fail to successfully commercialize or establish collaborative relationships to commercialize or develop certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
We do not yet know the full extent and magnitude of the impacts that these any future developments will have on our business, on the healthcare system, or on the global economy.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion growth of our business will may be delayed or stopped.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On January 23, 2026 (the “Closing Date”), we completed the previously announced Merger (as defined below) with Astria (as defined below). Pursuant to the Merger, on the Closing Date, we acquired Astria’s lead product candidate navenibart, an injectable monoclonal antibody designed to inhibit plasma kallikrein for the treatment of HAE. Navenibart is currently in Phase 3 clinical development, and the FDA has granted Fast Track and Orphan Drug designations to navenibart for the treatment of HAE. In addition, the European Commission has granted Orphan Medicinal Product Designation to navenibart for the treatment of HAE. The goal for navenibart is to develop a potentially best-in-class injectable prophylactic therapy with a differentiated every 3- and 6-month administration schedule, which could offer significant improvements over existing injectable options and address key unmet needs in the HAE patient community.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Pursuant to the Merger, on the Closing Date, we acquired STAR-0310, which is a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology for the treatment of atopic dermatitis (“AD”) and potentially other indications. STAR-0310 was designed as a potentially best-in-class, long-acting OX40 inhibitor with the goal of addressing the need for a safe, effective, and infrequently administered AD treatment. AD is an immune disorder associated with loss of skin barrier function and itching and is caused by diverse mechanisms, spanning the spectrum of T cell-driven pathology. STAR-0310 is currently in a Phase 1a trial to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy subjects. We plan to seek strategic alternatives for this asset.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On November 6, 2025, we announced new data demonstrating the early and negative psychosocial impact of HAE and resulting emergency department and hospital visits on pediatric patients and their caregivers, as well as new one-year data from the ongoing APeX-P clinical trial showing early and sustained reductions in monthly attack rates over one year in pediatric patients with HAE aged 2 to <12 years treated with once-daily ORLADEYO.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On February 26, 2026, we announced that new positive, interim results from the long‑term, open‑label ALPHA‑SOLAR trial show sustained, robust HAE attack suppression with navenibart administered every three and six months.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
As previously disclosed, on June 27, 2025, we entered into a stock purchase agreement (the “Stock Purchase Agreement”) with BioCryst Ireland Limited (“BioCryst Ireland”), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, and Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (“Neopharmed”). On October 1, 2025 (the “Closing”), under the terms of the Stock Purchase Agreement, we sold to Neopharmed all of our equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to our European ORLADEYO business. At the Closing, we received total cash proceeds of $254.5 million, comprised of the purchase price of $250.0 million and customary purchase price adjustments of $4.5 million as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay us up to $14.0 million if certain revenue milestones are achieved prior to December 31, 2032. In connection with the Closing, Neopharmed also paid a $15.0 million royalty release fee to RPI 2019 Intermediate Finance Trust. See “Note 2—Divestiture of BioCryst Ireland Limited” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about the sale of the European ORLADEYO business.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On October 8, 2025, we used a portion of the proceeds from the sale of the European ORLADEYO business to pay off in full the outstanding principal balance of $198.7 million and terminate the Pharmakon Loan Agreement (as defined below).
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On October 14, 2025, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Astria Therapeutics, Inc., a Delaware corporation (“Astria”). Pursuant to the Merger Agreement, on the Closing Date, Merger Sub merged with and into Astria, with Astria surviving as a wholly owned subsidiary of the Company (the “Merger”).
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Under the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of Astria common stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time (excluding shares held by BioCryst, Astria or their wholly owned subsidiaries or dissenting stockholders) was converted into the right to receive (i) 0.59 of a share of the Company’s common stock (and, if applicable, cash in lieu of fractional shares), and (ii) $8.55 in cash, without interest, subject to certain adjustments and applicable withholding taxes. Holders of Astria’s Series X Convertible Preferred Stock, warrants, and certain options were treated as set forth in the Merger Agreement.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On the Closing Date, we also entered into a Loan Agreement (the “Blackstone Loan Agreement”) with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., (together, “Blackstone”), as the Blackstone representatives thereunder, the guarantors from time to time party thereto, the lenders from time to time party thereto, and Wilmington Trust, National Association, as agent, pursuant to which the lenders funded initial term loans in the aggregate principal amount of $400.0 million (the “Term Loans”). Subject to the mutual agreement between the Company,
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Blackstone and the lenders, we may request additional term loans up to an aggregate principal amount not exceeding $150.0 million. Our obligations under the Blackstone Loan Agreement are secured by a security interest in, subject to certain exceptions, substantially all of our and our subsidiaries’ assets. We used the proceeds from the Term Loans (i) to pay the cash portion of the consideration required to consummate the Merger and pay other expenses related to the Merger and (ii) to pay the fees, premiums, expenses and other transaction costs incurred in connection with the transactions related to the Merger and the Loan Agreement. The maturity date of the Term Loans under the Loan Agreement is January 23, 2031, the fifth anniversary of the Closing Date. See “Note 21—Subsequent Events” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about the Blackstone Loan Agreement.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
The goal of our overall complement program is to advance first-in-class and/or best-in-class compounds across multiple pathways in the complement system to treat complement-mediated diseases. We are pursuing oral medicines and protein therapeutics directed at targets across the classical, lectin, terminal, and alternative pathways of the complement system, including the therapies listed below.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Oral C5 Inhibitor. We are developing an oral C5 inhibitor that could be the first targeted oral therapy with competitive efficacy to currently-approved injected and infused anti-C5 therapies, such as eculizumab and ravulizumab. A drug with this profile could enable patients to switch from infused therapy and address their disease earlier in the treatment paradigm.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Oral C2 Inhibitor. We are developing a classical and lectin pathway complement inhibitor. An oral C2 inhibitor developed by us could be first-in-class and allow patients to switch from infused therapy and address their disease earlier in the treatment paradigm.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Bifunctional Complement Inhibitor. We are developing a bifunctional complement inhibitor anti-C2 monoclonal antibody that could be a first-in-class combined inhibitor of the classical, lectin and alternative pathways of the complement system to treat complex complement-mediated diseases that are influenced by multiple complement pathways.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On October 14, 2024, we announced new real-world evidence on the use of ORLADEYO demonstrating that patients with HAE in the United States experience significant reductions in healthcare resource utilization, including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On October 24, 2024, we announced new real-world comparative research on the use of ORLADEYO that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other long-term prophylactic (“LTP”) therapies for HAE. We also announced new real-world evidence showing statistically significant and sustained HAE attack rate reductions after initiating ORLADEYO in patients with HAE, regardless of their C1-inhibitor deficiency status, and new findings from an HAE patient survey confirming patient preference for an oral LTP therapy.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On November 4, 2024, we announced that since launch, approximately half of patients who have started ORLADEYO have switched from another prophylactic therapy. We have begun the observational Phase 4 APeX-T study, designed to generate real-world data to inform physicians on the best individual approaches to support transition to ORLADEYO.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On November 18, 2024, we announced that the Health Services Executive in Ireland recommended ORLADEYO for the routine prevention of recurrent attacks of HAE in eligible patients 12 years and older.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On February 12, 2025, we announced that Infarmed in Portugal has recommended ORLADEYO for the routine prevention of recurrent attacks of HAE in eligible patients 12 years and older. With this recommendation, ORLADEYO is now reimbursed in all major countries in Western Europe, except the Netherlands, which is expected in the first half of 2025.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On February 24, 2025, we announced that a new market tracking survey of 60 HAE treaters showed that 97 percent are considering prescribing ORLADEYO and 59 percent (up from 26 percent 18 months prior) of current prescribers indicate they are extremely likely to prescribe for more of their patients. In addition, we announced that additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-inhibitor deficiency and normal C1-inhibitor levels and function. Patient-reported outcomes also showed willingness to change long-term prophylaxis and improved treatment satisfaction across varying levels of attack frequency and severity after ORLADEYO initiation.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
The following table summarizes our research and development expenses for the periods indicated (in thousands). Certain prior period amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the total research and development expenses.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash used in financing activities of $5.8 $349.9 million primarily consisted of the repayment of Pharmakon term loan principal and related prepayment premium and fees totaling $309.9 million, $22.9 million in principal payments on royalty financing obligations, $15.5 million in payments of royalty release fees to RPI and OMERS in connection with the sale of the Company’s European ORLADEYO business to Neopharmed, and $8.8 million of withholding taxes paid on stock-based awards and principal payments on finance lease liabilities, awards, partially offset by $9.1 million of net proceeds from common stock issued under stock-based compensation plans.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including the development progress and results of our collaborative agreements current and proposed clinical trials for our product candidates, candidates; the progress made in the manufacturing of our lead product candidates; the success of our commercialization efforts for, and market acceptance of, our products; the overall progression of our other programs; our business development activities; the amount of funding or assistance, if any, we receive from new partnerships with third parties for the development and/or commercialization of our products and product candidates, candidates; the development progress of any collaborative agreements for our product candidates; and the amount and timing of funding we receive, if any, from U.S.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
See “Risk Factors—Risks Relating to Our Business—Financial and Liquidity Risks” and “Risk Factors—Risks Relating to Our Business—Risks Relating to Drug Development and Commercialization—If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations” in Part I, Item 1A of this report for further discussion of the risks related to obtaining additional capital.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Non-cash items primarily consisted of $67.6 million of non-cash interest expense and $65.4 million of stock-based compensation expense, $56.0 million of non-cash interest expense on royalty financing obligations, and $11.6 million of non-cash interest expense on secured term loan and amortization of debt issuance costs, partially offset by $11.5 million of amortization of premiums and discounts on investments.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Interest expense for the year ended December 31, 2024 was is primarily comprised of $56.0 million of non-cash interest expense due to the amortization of interest associated with the royalty financing obligations and $41.5 million of interest expense, expense associated with the borrowings under the Pharmakon Loan Agreement (as defined below), including the amortization of the deferred financing costs, associated with the borrowings under the Pharmakon Loan.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Under the Royalty Purchase Agreements, RPI and OMERS are entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the “Key Territories”), and other markets where we sell ORLADEYO directly or through distributors.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We are a global biotechnology company with a focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with hereditary angioedema (“HAE”) and other rare diseases. these conditions.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Certain of the customary negative covenants limit the our ability of the Company and certain of its our subsidiaries to, among other things, dispose of assets; assets, engage in mergers, acquisitions, acquisitions and similar transactions; transactions, incur additional indebtedness; indebtedness, grant liens; liens, make investments; investments, pay dividends or make distributions or certain other restricted payments in respect of equity; equity, prepay certain other indebtedness; indebtedness, enter into restrictive agreements; agreements, undertake fundamental changes; changes or amend certain material contracts, among other customary covenants, in each case subject to certain exceptions.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
By utilizing our existing commercial capabilities and focusing primarily on rare disease markets, we believe that we can more effectively control the optimize our costs of, and our strategic allocation of financial strategically allocate resources toward, post-approval commercialization. to support long-term, sustainable growth.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our operating expenses are also difficult to predict and depend primarily on several factors, including research and development expenses, drug manufacturing, activities, including clinical research activities, activities and the ongoing requirements of our development programs, as well as the costs of commercialization, the availability of capital and drug manufacturing, direction from regulatory agencies, which are difficult to predict, and the factors discussed in the “Risk Factors” section in Part I, Item 1A of this report.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Avoralstat, delivered to the suprachoroidal space, is designed to provide high dose levels long-lasting exposure to the retinal vessels with long-lasting exposure, vessels, which could result in less frequent injections and a reduced burden on patients and the healthcare system.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
While our significant accounting policies are more fully described in “Note 1—Significant Accounting Policies and Concentrations of Risk” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report, we believe that the following accounting policies are the to be most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use used in the preparation of our consolidated financial statements.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.